KUKJEON PHARMACEUTICAL's (KOSDAQ:307750) Problems Go Beyond Poor Profit

The market shrugged off KUKJEON PHARMACEUTICAL Co., Ltd's (KOSDAQ:307750) weak earnings report. Despite the strength in the stock, we feel that investors should be cautious about some numbers in the earnings.

Check out our latest analysis for KUKJEON PHARMACEUTICAL

Zooming In On KUKJEON PHARMACEUTICAL's Earnings

In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF.

Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.

For the year to December 2023, KUKJEON PHARMACEUTICAL had an accrual ratio of 0.59. As a general rule, that bodes poorly for future profitability. To wit, the company did not generate one whit of free cashflow in that time. In the last twelve months it actually had negative free cash flow, with an outflow of ₩44b despite its profit of ₩4.82b, mentioned above. We also note that KUKJEON PHARMACEUTICAL's free cash flow was actually negative last year as well, so we could understand if shareholders were bothered by its outflow of ₩44b. However, as we will discuss below, we can see that the company's accrual ratio has been impacted by its tax situation. This would certainly have contributed to the weak cash conversion.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of KUKJEON PHARMACEUTICAL.

An Unusual Tax Situation

Moving on from the accrual ratio, we note that KUKJEON PHARMACEUTICAL profited from a tax benefit which contributed ₩3.0b to profit. It's always a bit noteworthy when a company is paid by the tax man, rather than paying the tax man. The receipt of a tax benefit is obviously a good thing, on its own. However, our data indicates that tax benefits can temporarily boost statutory profit in the year it is booked, but subsequently profit may fall back. Assuming the tax benefit is not repeated every year, we could see its profitability drop noticeably, all else being equal. So while we think it's great to receive a tax benefit, it does tend to imply an increased risk that the statutory profit overstates the sustainable earnings power of the business.

Our Take On KUKJEON PHARMACEUTICAL's Profit Performance

KUKJEON PHARMACEUTICAL's accrual ratio indicates weak cashflow relative to earnings, which perhaps arises in part from the tax benefit it received this year. On top of that, the unsustainable nature of tax benefits mean that there's a chance profit may be lower next year, certainly in the absence of strong growth. For the reasons mentioned above, we think that a perfunctory glance at KUKJEON PHARMACEUTICAL's statutory profits might make it look better than it really is on an underlying level. If you want to do dive deeper into KUKJEON PHARMACEUTICAL, you'd also look into what risks it is currently facing. When we did our research, we found 2 warning signs for KUKJEON PHARMACEUTICAL (1 is potentially serious!) that we believe deserve your full attention.

Our examination of KUKJEON PHARMACEUTICAL has focussed on certain factors that can make its earnings look better than they are. And, on that basis, we are somewhat skeptical. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.